title: CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
abstract: If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.
authors.affiliation: Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Reiman
authors.affiliation: Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
authors.forename: Jessica B
authors.initials: JB
authors.lastname: Langbaum
authors.affiliation: Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
authors.forename: Pierre N
authors.initials: PN
authors.lastname: Tariot
authors.affiliation: Grupo de Neurosciencias, Universidad de Antioquia, Calle 62 #52-59, Medellin, Colombia.
authors.forename: Francisco
authors.initials: F
authors.lastname: Lopera
authors.affiliation: Department of Neurology, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Bateman
authors.affiliation: Department of Neurology, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.
authors.forename: John C
authors.initials: JC
authors.lastname: Morris
authors.affiliation: Department of Neurology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.
authors.forename: Reisa A
authors.initials: RA
authors.lastname: Sperling
authors.affiliation: University of Southern California Alzheimer's Therapeutic Research Institute, 10182 Telesis Court, San Diego, CA 92121, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Aisen
authors.affiliation: Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Department of Neurology, Duke University Medical Center, 2200 West Main Street, Durham, NC 27705, USA.
authors.forename: Allen D
authors.initials: AD
authors.lastname: Roses
authors.affiliation: Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Department of Neurology, Duke University Medical Center, 2200 West Main Street, Durham, NC 27705, USA.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Welsh-Bohmer
authors.affiliation: Alzheimer's Association, Medical &Scientific Relations Division, 225 North Michigan Avenue, Chicago, IL 60601, USA.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Carrillo
authors.affiliation: Fidelity Biosciences Research Initiative, One Main Street, Cambridge, MA 02142, USA.
authors.forename: Stacie
authors.initials: S
authors.lastname: Weninger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D003299:Cooperative Behavior; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical; D042241:Early Diagnosis; D019983:Guideline Adherence; D006801:Humans; D033183:Interdisciplinary Communication; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D062706:Prodromal Symptoms; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D018697:Nootropic Agents